

7/4/03
17/103



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NI *et al.*

Appl. No. 09/042,583

Filed: March 17, 1998

For: **Death Domain Containing
Receptor 5**

Confirmation No. 5224

Art Unit: 1646

Examiner: Kaufman, Claire M.

Atty. Docket: 1488.1310002/EKS/EJH/SJE

RECEIVED
JUN 03 2003
TC 1700

Sixth Supplemental Information Disclosure Statement

RECEIVED
JUN 05 2003
TECH CENTER 1600/2900

Commissioner of Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Sixth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Fifth Supplemental Information Disclosure Statement filed on December 11, 2002, in connection with the above-captioned application. A copy of each document is also provided.

Applicants wish to direct the Examiner's attention to the Statutory Declarations and accompanying exhibits as follows:

Statutory Declaration of Avi Ashkenazi, signed March 14, 2003, with Exhibits AJA1 to AJA3, AJA5, and AJA7 to AJA10.

Exhibit AJA-4 was submitted previously as AL2 in Applicant's Fifth Supplemental Information Disclosure Statement, filed on December 11, 2002. Exhibit AJA-6 was submitted previously in Applicants First Information Disclosure Statement, filed on

06/02/2003 SSESHE1 00000080 09042583

01 FC:1806

180.00 OP

September 22, 1998. The above-listed documents were brought to the attention of the Applicants in connection with an opposition to an Australian application that essentially corresponds to the U.S. priority application in this case. A copy of the above-listed documents, exclusive of documents cited in previous Information Disclosure Statements, are enclosed and are listed on the accompanying form PTO-1449.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p); in addition:

I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Elizabeth J. Haanes, Ph.D.
Attorney for Applicants
Registration No. 42,613

Date: May 30, 2003

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



FORM PTO-1449

SIXTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH/SJEAPPLICATION NO.
09/042,583APPLICANT
NI *et al.*FILING DATE
March 17, 1998GROUP
1646

RECEIVED
JUN 03 2003
TC 1700

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

JUN 05 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	6	✓	Brojatsch, J., <i>et al.</i> , "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis," <i>Cell</i> 87:845-855, Cell Press (November 1996)
AS	6	✓	Chapman, B.S., "A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas," <i>FEBS Lett.</i> 374:216-220, Elsevier (1995)
AT	6	✓	Rabizadeh, S., <i>et al.</i> , "Induction of Apoptosis by the Low-Affinity NGF Receptor," <i>Science</i> 261:345-348, American Association for the Advancement of Science (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

MAY 30 2003

FORM PTO-1449

SIXTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH/SJEAPPLICATION NO.
09/042,583APPLICANT
NI *et al.*FILING DATE
March 17, 1998GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<input checked="" type="checkbox"/>	Tartaglia, L.A., <i>et al.</i> , "A Novel Domain within the 55 kd TNF Receptor Signals Cell Death," <i>Cell</i> 74:845-853, Cell Press (1993)
AS	<input checked="" type="checkbox"/>	Statutory Declaration of Avi J. Ashkenazi, signed March 14, 2003
AT	<input checked="" type="checkbox"/>	Curriculum vitae of Avi Ashkenazi

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

WITH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJH/SJEAPPLICATION NO.
09/042,583APPLICANT
Ni *et al.*FILING DATE
March 17, 1998GROUP
1646RECEIVED
JUN 03 2003
TC 1700

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED
JUN 05 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	8 ✓	Copy of provisional U.S. application 60/040,846, inventor Ni <i>et al.</i> , filed March 17, 1997
	AS	8 ✓	Copy of provisional U.S. application 60/054,021, inventor Ni <i>et al.</i> , filed July 29, 1997
	AT	8 ✓	Copy of U.S. application 08/857,216, inventor Ashkenazi, filed May 15, 1997

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.